Analysis of eplerenone in the FDA adverse event reporting system (FAERS) database: a focus on overall patient population and gender-specific subgroups

• Hauptverfasser: Xin Guan (Verfasst von), Yusi Yang (Verfasst von), Xinru Li (Verfasst von), Yue Feng (Verfasst von), Jizhen Li (Verfasst von), Xuewen Li (Verfasst von)
• Format: Buch
• Veröffentlicht: Frontiers Media S.A., 2024-07-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Introduction: Eplerenone is approved for the treatment of hypertension as well as symptomatic heart failure with reduced ejection fraction (HFrEF) following an acute myocardial infarction. However, the adverse events (AEs) have not been systematically analyzed. The aim of this study was to identify...